Background: A year ago, United Therapeutics (NASDAQ:UTHR) came out with a strong quarterly earnings report, and I wrote a bullish article on it titled United Therapeutics - A Low PE, Fast-Growing Biotech Stock.
Since then, the stock has appreciated almost 30%.
UTHR has risen 20% annually on average as a public company. However, it gets little attention.
The combination of a successful biopharmaceutical company, strong stock price performance over fifteen years, relatively little publicity and a low P/E has led me to be long this name.
This article explores UTHR and propounds a generally positive investment thesis for patient investors, though risks are present.
Introduction: United Therapeutics was founded by the current CEO to find...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|